Carbiotix (publ) ("Carbiotix") announces today that the company has signed a collaboration agreement with Food Marble Digestive Health Ltd. (“Food Marble”) of Dublin, Ireland, a leading provider of consumer digestive health tracking devices, to conduct a eight-week study to examine the correlation between digestive health and gut health during Q4 2019.
Food Marble (www.foodmarble.com) is a leading provider of consumer digestive health tracking services, offering the Food Marble AIRE, the first portable breath test and app to measure digestive health. Food Marble currently has over 12,000 customers using the Food Marble AIRE device from across the globe. The eight-week study, planned for Q4 2019, will be managed by Food Marble in Ireland with a group of 20 individuals and using two different prebiotic fibers, supported by gut health analysis services provided by Carbiotix in Sweden.
Kristofer Cook, CEO for Carbiotix, comments
“This collaboration agreement and study is a very important step on route to increasing the frequency and amount of gut health data that can be made available for an individual by making it easier to collect this data. By understanding the correlation between digestive health and gut health, one will be able to leverage the Food Marble digestive tracker to help diagnose and monitor gut health on a daily basis, supported and validated by more comprehensive gut health data based on fecal sampling. Eventually, the platform could be used to modify the dosing of Carbiotix therapeutic products in real-time. This first study will demonstrate whether the proposed correlation exists and serve as a basis to evaluate future collaborative opportunities between Carbiotix and Food Marble with regards to studies and the bundling of products and services.”
This information is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company’s contact person set out below on 8 October 2019.
Forward-looking statements This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
For further information:
Kristofer Cook, CEO
Carbiotix AB (CRBX) (www.carbiotix.com) is a biotechnology company developing Microbiome Modulator Therapeutics (MMT) that amplify the production of key metabolites for the treatment of different metabolic and chronic diseases. The company’s therapeutics are based on a propriety AXOS soluble fiber, isolated bacterial strains, and innovative formulations, supported by cost effective gut health testing services used to regularly diagnose and monitor gut health, as well as dose therapeutics.